Rights Issue Terms Finalized

Vineet Laboratories Limited has announced the complete terms for its rights issue following the Rights Issue Committee meeting held on December 17, 2025. The committee meeting, which commenced at 2:00 PM and concluded at 3:00 PM, finalized all key parameters including the record date of December 23, 2025, for determining eligible shareholders and confirmed the issue price at ₹30.00 per share.

Rights Entitlement ISIN Declared

The company has now disclosed the International Securities Identification Number (ISIN) for the Rights Entitlements as INE505Y20010, completing the regulatory framework for the upcoming rights issue. This announcement was made in accordance with SEBI circulars and Regulation 42 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Newspaper Publication Compliance

Vineet Laboratories has fulfilled its regulatory obligation under Regulation 84 of SEBI ICDR Regulations by publishing newspaper advertisements on December 29, 2025. The advertisements, confirming the completion of dispatch of Letter of Offer and Composite Application Forms, were published in three newspapers with wide circulation to ensure comprehensive investor awareness.

Issue Structure and Timeline

The rights issue will offer 99,87,258 fully paid-up equity shares with an entitlement ratio of 13:12, meaning eligible shareholders will receive 13 new rights equity shares for every 12 shares held on the record date. The issue is scheduled to open on January 1, 2026, and close on January 21, 2026, with the full amount of ₹30.00 per share payable on application.

Shareholding Impact and Next Steps

The rights issue will significantly expand the company's equity base from the current outstanding equity shares of 92,19,008 to 1,92,06,266 shares, assuming full subscription. The Rights Entitlements of eligible equity shareholders as on the record date will be credited prior to the issue opening date in their respective demat accounts under the declared ISIN INE505Y20010.

Vineet Laboratories Limited , a player in the Indian pharmaceutical sector, has recently witnessed significant insider trading activity. Promoters of the company have sold substantial equity shares through market transactions, as disclosed in recent regulatory filings.

Key Details of the Share Sale

According to the latest information, promoters of Vineet Laboratories Limited sold 9,40,975 equity shares through open market transactions on the National Stock Exchange (NSE) across three separate disposal events. This sale has resulted in a decrease in the collective promoter holding from 17.75% to 12.95% of the company's total share capital, which stands at 92,19,008 shares.

Regulatory Compliance

The company has duly informed both the BSE Limited and the National Stock Exchange of India Limited about these transactions. This disclosure aligns with the company's commitment to transparency and adherence to regulatory requirements, including Regulation 7(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015.

Market Impact

This significant insider selling may attract attention from market participants and could potentially impact the stock's performance in the short term. The reduction in promoter holding from 17.75% to 12.95% represents a change in the ownership structure of the company.

Company Background

Vineet Laboratories Limited, with its registered office in Hyderabad, operates in the pharmaceutical sector.

Investors and market analysts may want to monitor Vineet Laboratories' stock performance and any further disclosures from the company. As always, it's advisable for investors to conduct thorough research and consider multiple factors before making investment decisions based on insider trading activities.